Determinants of RASistance to anti-epidermal growth factor receptor agents

被引：63

作者：

Baselga, Jose ^{[1
,2
]}

Rosen, Neal ^{[3
]}

机构：

[1] Vall Dhebron Univ Hosp, Barcelona, Spain

[2] Vall Dhebron Inst Oncol, Barcelona, Spain

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 10期

关键词：

D O I：

10.1200/JCO.2007.15.3700

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1582 / 1584

页数：3

共 22 条

[11] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J].

Khambata-Ford, Shirin ;

Garrett, Christopher R. ;

Meropol, Neal J. ;

Basik, Mark ;

Harbison, Christopher T. ;

Wu, Shujian ;

Wong, Tai W. ;

Huang, Xin ;

Takimoto, Chris H. ;

Godwin, Andrew K. ;

Tan, Benjamin R. ;

Krishnamurthi, Smitha S. ;

Burris, Howard A., III ;

Poplin, Elizabeth A. ;

Hidalgo, Manuel ;

Baselga, Jose ;

Clark, Edwin A. ;

Mauro, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3230-3237

[12] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].

Lièvre, A ;

Bachet, JB ;

Le Corre, D ;

Boige, V ;

Landi, B ;

Emile, JF ;

Côté, JF ;

Tomasic, G ;

Penna, C ;

Ducreux, M ;

Rougier, P ;

Penault-Llorca, F ;

Laurent-Puig, P .

CANCER RESEARCH, 2006, 66 (08) :3992-3995

[13] Timeline - RAS oncogenes: the first 30 years [J].

Malumbres, M ;

Barbacid, M .

NATURE REVIEWS CANCER, 2003, 3 (06) :459-465

[14] KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].

Massarelli, Erminia ;

Varella-Garcia, Marileila ;

Tang, Ximing ;

Xavier, Ana C. ;

Ozburn, Natalie C. ;

Liu, Diane D. ;

Bekele, Benjamin N. ;

Herbst, Roy S. ;

Wistuba, Ignacio I. .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :2890-2896

[15] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J].

Mellinghoff, IK ;

Wang, MY ;

Vivanco, I ;

Haas-Kogan, DA ;

Zhu, SJ ;

Dia, EQ ;

Lu, KV ;

Yoshimoto, K ;

Huang, JHY ;

Chute, DJ ;

Riggs, BL ;

Horvath, S ;

Liau, LM ;

Cavenee, WK ;

Rao, PN ;

Beroukhim, R ;

Peck, TC ;

Lee, JC ;

Sellers, WR ;

Stokoe, D ;

Prados, M ;

Cloughesy, TF ;

Sawyers, CL ;

Mischel, PS .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) :2012-2024

[16] Epidermal growth factor receptor targeting in cancer [J].

Mendelsohn, John ;

Baselga, Jose .

SEMINARS IN ONCOLOGY, 2006, 33 (04) :369-385

[17]

Miller VA, 2006, J CLIN ONCOL, V24, p364S

[18] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

[19] KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J].

Pao, W ;

Wang, TY ;

Riely, GJ ;

Miller, VA ;

Pan, QL ;

Ladanyi, M ;

Zakowski, MF ;

Heelan, RT ;

Kris, MG ;

Varmus, HE .

PLOS MEDICINE, 2005, 2 (01) :57-61

[20]

Philip PA, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.09.6040

← 1 2 3 →